Picture Berlin Partner Berlin-Brandenburg Healthcare Industries Cluster 650x80px
Collaboration › Details

AstraZeneca–Proteros: small-molecule cancer drugs, 202106– collab r+d + license agreem with research funding + $62m milestones + royalties


Period Period 2021-06-02
Organisations Partner, 1st AstraZeneca plc (LSE: AZN)
  Group AstraZeneca (Group)
  Partner, 2nd Proteros Biostructures GmbH
  Group Proteros (Group)
Products Product small-molecule cancer drug
  Product 2 drug discovery
Person Person Galbraith, Susan (AstraZeneca 201212 VP + Head Oncology Innovative Medicines Unit)

Proteros Biostructures GmbH. (6/2/21). "Press Release: Proteros Enters into Oncology Collaboration and License Agreement with AstraZeneca". Martinsried.

Proteros to receive research funding and milestone payments plus royalties

Proteros biostructures GmbH (“Proteros”) today announced that it has signed an agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to jointly discover and develop novel small molecules for the potential treatment of various types of cancer.

The collaboration brings together Proteros’ discovery capabilities which are tailored to unlock even the most technically challenging drug targets with AstraZeneca’s expertise in target biology and medicinal chemistry to jointly discover novel lead compounds which will be further developed, manufactured, and commercialized by AstraZeneca.

Under the agreement, AstraZeneca will provide research funding and Proteros will be eligible for success-based research, development, and commercial milestone payments up to 62 million EUR plus tiered royalties on annual net sales.

“We believe that advances in epigenomic capabilities will bring forward the next wave of innovation in cancer development through the discovery and development of novel small molecules,” said Susan Galbraith, Senior Vice President and Head of Research and Early Development, Oncology R&D, AstraZeneca. “Proteros’ proprietary discovery platform enables us to screen epigenetic targets in a physiologically relevant setting, supporting accelerated discovery and development of the next wave of anti-cancer medicines.”

“We are delighted AstraZeneca has selected Proteros to act as their discovery engine for a number of novel and very relevant oncology targets,” said Dr Torsten Neuefeind, Proteros’ CEO. “These types of targets pose a number of challenges that Proteros’ discovery platform is uniquely positioned to overcome.”

About Proteros biostructures GmbH

Proteros is a privately held early-stage services provider in structure-based drug discovery with a cutting-edge discovery engine tailored to unlock even the most technically challenging targets. Proteros’ work is built on scientific excellence and supports its clients to reach the right results and accelerate their overall research timelines. Proteros supports most of the world’s 20 largest pharma companies and more than 250 pharmaceutical and biotech partners in the US, Europe and Japan.

For more information please visit

Proteros contact information

Dr. Torsten Neuefeind
Chief Executive Officer
Phone: +49 89 700761-0

Record changed: 2021-06-13


Picture Berlin Partner Hotspot for Startups 650x80px

More documents for AstraZeneca (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture [iito] Fighting Customers 650x80px

» top